A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Clinical trial NCT01676558 · UNKNOWN

Trial details

NCT number: NCT01676558
Sponsor: Korea Cancer Center Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed or Refractory Diffuse Large B Cell Lymphoma

Start date: 2012-06-01
Primary completion: 2016-06-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.